Literature DB >> 2222115

Mast cells and idiopathic lung fibrosis.

T I Fortoul1, R Barrios.   

Abstract

Mast cells are usually related with allergic reactions in the lung. This cells has a biochemical repertoire capable of modulate inflammatory reactions in this organ. The relation of this cell with idiopathic pulmonary fibrosis (IPF), has not been studied in depth. There is no agreement in which is the best technique for counting mast cells and what are the normal counts of these cells in the lung. We analyse some of the reported "normal values" and the differences within IPF and patients with nonfibrotic lung diseases. The results of the present study demonstrate that the largest population of mast cells in IPF patients were the interstitium (342 +/- 83 cells) compared with the nonfibrotic patients (31 +/- 8 cells), and almost equal in both groups of patients in the subpleural, peribronchiolar and perivascular areas. However, it is necessary to unify criteria, in order to define what the normal values for mast cells in the lung are.

Entities:  

Mesh:

Year:  1990        PMID: 2222115

Source DB:  PubMed          Journal:  Arch Invest Med (Mex)        ISSN: 0066-6769


  3 in total

1.  Activated MCTC mast cells infiltrate diseased lung areas in cystic fibrosis and idiopathic pulmonary fibrosis.

Authors:  Cecilia K Andersson; Annika Andersson-Sjöland; Michiko Mori; Oskar Hallgren; Annie Pardo; Leif Eriksson; Leif Bjermer; Claes-Göran Löfdahl; Moises Selman; Gunilla Westergren-Thorsson; Jonas S Erjefält
Journal:  Respir Res       Date:  2011-10-20

2.  Effect of heparin and related glycosaminoglycan on PDGF-induced lung fibroblast proliferation, chemotactic response and matrix metalloproteinases activity.

Authors:  M Sasaki; M Kashima; T Ito; A Watanabe; M Sano; M Kagaya; T Shioya; M Miura
Journal:  Mediators Inflamm       Date:  2000       Impact factor: 4.711

Review 3.  Are mast cells instrumental for fibrotic diseases?

Authors:  Catherine Overed-Sayer; Laura Rapley; Tomas Mustelin; Deborah L Clarke
Journal:  Front Pharmacol       Date:  2014-01-21       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.